Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590294003> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2590294003 endingPage "216" @default.
- W2590294003 startingPage "216" @default.
- W2590294003 abstract "216 Background: Enzalutamide is an androgen receptor signaling inhibitor that is FDA-approved for post-docetaxel mCRPC patients. Overlapping mechanisms of action and clinical evidence for an interaction between taxanes and androgen-targeted therapies complicates optimal sequencing of taxanes and enzalutamide. We retrospectively evaluated the efficacy of enzalutamide pre- (preD) and post-docetaxel (postD) therapy. Methods: Men with mCRPC who received enzalutamide preD or postD were identified from a single institution database. We investigated factors influencing enzalutamide activity by using univariate and multivariable Cox regression models, with particular attention to whether or not prior docetaxel had been used. Outcome measures of interest were time-to-PSA-progression (TTPP) and progression-free-survival (PFS). Results: A total of 72 patients received enzalutamide at our institution: 22 were preD and 50 were postD. Median duration of enzalutamide therapy was 5.5 mo (range, 0.7–33.6 mo). In univariate Cox regression analysis, the following factors were predictive of TTPP: ECOG status (≥1 vs 0), number of metastases (>5 vs 0-5), hemoglobin and albumin. Prior docetaxel treatment was associated with a trend towards shorter TTPP on enzalutamide (HR 0.54, 95%CI 0.27–1.10, P=0.09). The following factors were predictive of PFS in univariate analysis: ECOG status, number of metastases, hemoglobin and albumin. Prior docetaxel therapy was associated with a trend towards shorter PFS on enzalutamide (HR 0.57, 95%CI 0.29–1.13, P=0.10). Conclusions: These data suggest numerically inferior TTPP and PFS outcomes to enzalutamide in men previously treated with docetaxel compared to men who were docetaxel-naïve, although the small sample size precludes statistically significant results. This potentially supports the hypothesis of cross-resistance between enzalutamide and docetaxel." @default.
- W2590294003 created "2017-03-03" @default.
- W2590294003 creator A5009105768 @default.
- W2590294003 creator A5012074439 @default.
- W2590294003 creator A5053929222 @default.
- W2590294003 creator A5075880342 @default.
- W2590294003 creator A5077558876 @default.
- W2590294003 date "2014-02-01" @default.
- W2590294003 modified "2023-09-28" @default.
- W2590294003 title "Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)." @default.
- W2590294003 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.216" @default.
- W2590294003 hasPublicationYear "2014" @default.
- W2590294003 type Work @default.
- W2590294003 sameAs 2590294003 @default.
- W2590294003 citedByCount "2" @default.
- W2590294003 countsByYear W25902940032015 @default.
- W2590294003 countsByYear W25902940032016 @default.
- W2590294003 crossrefType "journal-article" @default.
- W2590294003 hasAuthorship W2590294003A5009105768 @default.
- W2590294003 hasAuthorship W2590294003A5012074439 @default.
- W2590294003 hasAuthorship W2590294003A5053929222 @default.
- W2590294003 hasAuthorship W2590294003A5075880342 @default.
- W2590294003 hasAuthorship W2590294003A5077558876 @default.
- W2590294003 hasConcept C121608353 @default.
- W2590294003 hasConcept C126322002 @default.
- W2590294003 hasConcept C126894567 @default.
- W2590294003 hasConcept C143998085 @default.
- W2590294003 hasConcept C144301174 @default.
- W2590294003 hasConcept C2776551883 @default.
- W2590294003 hasConcept C2780192828 @default.
- W2590294003 hasConcept C2781190966 @default.
- W2590294003 hasConcept C38180746 @default.
- W2590294003 hasConcept C50382708 @default.
- W2590294003 hasConcept C61367390 @default.
- W2590294003 hasConcept C71924100 @default.
- W2590294003 hasConceptScore W2590294003C121608353 @default.
- W2590294003 hasConceptScore W2590294003C126322002 @default.
- W2590294003 hasConceptScore W2590294003C126894567 @default.
- W2590294003 hasConceptScore W2590294003C143998085 @default.
- W2590294003 hasConceptScore W2590294003C144301174 @default.
- W2590294003 hasConceptScore W2590294003C2776551883 @default.
- W2590294003 hasConceptScore W2590294003C2780192828 @default.
- W2590294003 hasConceptScore W2590294003C2781190966 @default.
- W2590294003 hasConceptScore W2590294003C38180746 @default.
- W2590294003 hasConceptScore W2590294003C50382708 @default.
- W2590294003 hasConceptScore W2590294003C61367390 @default.
- W2590294003 hasConceptScore W2590294003C71924100 @default.
- W2590294003 hasIssue "4_suppl" @default.
- W2590294003 hasLocation W25902940031 @default.
- W2590294003 hasOpenAccess W2590294003 @default.
- W2590294003 hasPrimaryLocation W25902940031 @default.
- W2590294003 hasRelatedWork W1652439388 @default.
- W2590294003 hasRelatedWork W2135620818 @default.
- W2590294003 hasRelatedWork W2590294003 @default.
- W2590294003 hasRelatedWork W2770702948 @default.
- W2590294003 hasRelatedWork W2901274396 @default.
- W2590294003 hasRelatedWork W2921176969 @default.
- W2590294003 hasRelatedWork W3023947295 @default.
- W2590294003 hasRelatedWork W3156855168 @default.
- W2590294003 hasRelatedWork W4205706045 @default.
- W2590294003 hasRelatedWork W4229076799 @default.
- W2590294003 hasVolume "32" @default.
- W2590294003 isParatext "false" @default.
- W2590294003 isRetracted "false" @default.
- W2590294003 magId "2590294003" @default.
- W2590294003 workType "article" @default.